Special channel feed – Endpoints News

Special channel feed

The Endpoints 11: They've got mad money and huge ambitions. It's time to go big or go home

4 years ago

From bench to boardroom: 20 of the most influential biopharma R&D executives in drug development

4 years ago

The top 10 pipeline blowups, setbacks and snafus for H1 2021

4 years ago

Legacies: 60 biopharma pioneers over 60 who helped birth a tech revolution in the making

5 years ago

The Endpoints 100 survey: CEOs changed the way biotechs operate during the pandemic. Things will never be the same again

5 years ago

The 20(+1) under 40: Inside the next generation of biotech leaders

5 years ago

The 2021 top 100 biopharma investors: As the pandemic hit and IPOs boomed, VCs swung into action like never before

5 years ago

2020’s NDA list is packed with commercial firsts — from historic to haphazard. Have we reached a tipping point?

5 years ago

Special report: Twenty extraordinary women blazing trails in biopharma R&D — Covid-19 and beyond

5 years ago

The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn't going to stop them

5 years ago

The 20 under 40: Inside the next generation of biopharma leaders

6 years ago

The E100 biotech survey: Execs are hunkering down for the pandemic, worried about longterm fallout — but eager to see biopharma make a difference

6 years ago

The top 10 biopharma pipeline blowups, setbacks and snafus for H2 2019

6 years ago

Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?

6 years ago

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

6 years ago

The $102B club: The top 15 R&D spenders in the global biopharma business — 2019 edition

6 years ago

The top 10 pipeline blowups, setbacks and snafus for H1 2019

6 years ago

Biotech execs predict big M&A deals ahead as mood shifts in wake of a 2018 hangover — Endpoints 100

7 years ago

The top 10 pipeline blowups, setbacks and snafus for H2 2018

7 years ago

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

7 years ago

The top 10 stories from Endpoints News in 2018

7 years ago

What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs

7 years ago

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

7 years ago

Global reach: The top 25 biopharma companies in the world

7 years ago

First page Previous page 1 234 Next page Last page